Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Meeting the New Regulatory Requirements in Sartan API Production

Manufacturer of APIs are now required to review their manufacturing processes and prove the absence of nitrosamine impurities. This whitepaper outlines the regulations and a case study on how Dr. Reddy’s Sartan API’s (such as Valsartan) already addresses future requirements.

You can review our Sartan portfolio by clicking on the following links:

Valsartan - https://api.drreddys.com/product/valsartan

Losartan - https://api.drreddys.com/product/losartan-potassium

Telmisartan

Irbesartan - https://api.drreddys.com/product/irbesartan

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

X

Have you booked your
CPHI Japan meeting slot yet?

Join us at booth: 5N-12

17th-19th April 2024

East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan

Schedule a meeting